

## Interpretation of FIB-4 and ELF tests in metabolic dysfunction-associated steatotic liver disease (MASLD)

### Age < 35 years

#### ELF <9.0

**Low risk for advanced liver fibrosis.**

Treat metabolic risk factors and if there is ongoing risk suggest repeating test in 3 years.

#### ELF ≥9.0

**High risk for advanced liver fibrosis.**

Recommend referral to Metabolic Hepatology Clinic.

### Age ≥ 35 years

#### FIB-4 <1.3

**Low risk for advanced liver fibrosis.**

Treat metabolic risk factors and if there is ongoing risk suggest repeating test in 3 years.

#### FIB-4 1.3 - 2.67 (Indeterminate)

##### ELF <9.5

**Low risk for advanced liver fibrosis.**

Treat metabolic risk factors and if there is ongoing risk suggest repeating test in 3 years.

##### ELF ≥9.5

**High risk for advanced liver fibrosis.**

Recommend referral to Metabolic Hepatology Clinic.

#### FIB-4 >2.67

**High risk for advanced liver fibrosis.**

Recommend referral to Metabolic Hepatology Clinic.

If you have any queries regarding the interpretation of these results, if there are any atypical clinical features or hepatic comorbidity, please contact the Hepatology email advice line on [orh-tr.oxon.hepatologyadvice@nhs.net](mailto:orh-tr.oxon.hepatologyadvice@nhs.net)

We like to offer all patients with MASLD access to clinical trials. If your patient is interested, please email [nellia.sande@ouh.nhs.uk](mailto:nellia.sande@ouh.nhs.uk)